mycosis fungoides (n = 35). Nineteen normal skin samples from surgical quadrantectomies were used as negative controls. The presence of chlamydial DNA was investigated by using three polymerase chain reaction (PCR) protocols allowing the amplification of the 16SrRNA gene and the 16S23S region: touchdown enzyme time release-PCR, 1 outer membrane protein (ompA) 7 and heat-shock protein 60
(hsp60). 8 The last protocol allows the distinction between C. psittaci and other Chlamydiae (C. abortus, C. caviae, C. felis).
Chlamydia trachomatis and C. pneumoniae infections were analysed by amplifying the 16S rRNA gene, and amplification of the b-globin gene was carried out as control of DNA suitability. 1 All PCR products were analysed by agarose gel electrophoresis, fragment size quantification and direct sequencing. C. psittaci DNA sequences were found in one (5%) of the skin biopsies used as controls. Among the lymphomas, C. psittaci DNA was detected in one DLBCL (6%; Fisher exact test P = 1AE00), in four follicular lymphomas (17%; P = 0AE36) ( Fig. 1 ) and in one MZL (3%; P = 1AE00), whereas all cases of mycosis fungoides were negative (0%; P = 0AE35). One case of follicular lymphoma was positive for C. pneumoniae. The different PCR protocols showed a good concordance, with positivity in at least two of the three PCRs in all positive cases (Table 1) .
This study showed that the prevalence of chlamydial infections is low in primary cutaneous lymphomas, with similar rates between DLCBL, MZL, mycosis fungoides and normal skin samples, whereas a nonsignificant trend to a higher prevalence of C. psittaci infection was observed in follicular lymphomas. This nonsignificant difference may simply be due to the relatively small subgroup size; however, the observation that C. psittaci prevalence is significantly higher in follicular lymphoma (four of 24, 17%) in comparison to all the other cutaneous lymphomas as a whole (two of 84, 2%; Fisher exact test P = 0AE02) suggests that this association deserves to an association between C. pneumoniae and mycosis fungoides was not detected. These figures confirm the preliminary results of our previous study. 2 The main differences between the two studies are follicular lymphoma, a distinct clinicopathological entity recognized by the updated 2008 WHO classification and not included in the previous study, and anaplastic largecell lymphoma, which was not part of the present series.
Overall, both studies suggest that chlamydial infections do not play a major role in the development and growth of mycosis fungoides and the most common forms of cutaneous B-cell lymphomas.
The present study has some limitations. Firstly, skin control samples were not taken from healthy individuals but were collected from patients with breast cancer. However, an interpretation bias can be excluded bona fide as histopathological analysis ruled out any neoplastic and inflammatory abnormality, and C. psittaci DNA prevalence in these controls (5%) was in line with data from hundreds of controls in previous studies 1,2 and with C. psittaci seroprevalence in the general European population (0-5%). 10 Secondly, DNA samples were collected mostly from single lesions, which does not take into account that cutaneous lymphomas are often multifocal diseases and that a fraction of patients with undetectable C. psittaci in the biopsied lesion could actually be infected by C. psittaci in other lesions or organs. Unfortunately, serological data and analysis on peripheral blood mononuclear cells (PBMC) were not available. However, the use of these methods would hardly improve the detection rate because of the low specificity of available serological assays, 3 and the fact that C. psittaci infection in PBMC is present only in some patients with C. psittaci-positive lymphoma. 1 Moreover, the superiority of the assessment of C. psittaci infection on both tumour tissue and PBMC with respect to those performed exclusively on diagnostic samples in patients with multifocal or disseminated lymphoma remains to be addressed. Funding sources: this work was supported in part by grants from Associazione Italiana per la Ricerca sul Cancro (to R.D., contract 10301). E.P. is a fellow of the Fondazione Italiana per la Ricerca sul Cancro.
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An exploratory 1 H-nuclear magnetic resonance metabolomics study reveals altered urine spectral profiles in infants with atopic dermatitis and little information is available about potential biomarkers. These facts make an easy and noninvasive test for evaluation of infant AD greatly desired by healthcare workers and parents. Metabolomics provides a new approach and opportunity to explore the metabolic effects of many conditions in individuals, 3, 4 and recent evidence has demonstrated that it can be usefully employed in the characterization of airway biochemical fingerprints in children with allergic asthma. 5 Nuclear magnetic resonance (NMR) spectra of biofluids contain signals from hundreds of metabolites. Chemometric approaches, such as principal component analysis (PCA) or cluster analyses, can be used to map the spectra in multivariate space where each sample occupies a position based on its metabolite composition. We explored the possibility of detecting metabolite-level changes correlated with AD in children by applying a metabolomic analysis of urine samples. Twenty children with AD, 13 boys and seven girls, aged 6-10 months, diagnosed by a staff physician (D.G.P.) according to the U.K. working party's criteria 6 and referred to the outpatient clinic of the Allergic Diseases Section of the Department of Life and Reproduction Science, were enrolled in the study. Twelve age-matched children, four male and eight female, without any clinical manifestation of AD or other known acute or chronic disease served as controls. The children were recruited in a narrow age range (6-10 months) to minimize biases due to external factors such as diet variability. It was further expected that the 
